CRC Research Update — November 14, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Saturday, November 14, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
RESEARCH
Compact plasma ctDNA panel detects oncogenic variants in 91% of evaluable newly diagnosed metastatic CRC patientsA 10-gene hybrid-capture sequencing panel identified baseline oncogenic variants in 32 of 35 evaluable patients (91.4%) with newly diagnosed unresectable metastatic colorectal cancer, showing 84.2% sensitivity and 100% specificity compared with routine tissue PCR for shared RAS/BRAF targets. (Int J Mol Sci)
-
SCREENING
Multi-target stool DNA testing yields 19% advanced neoplasia even after prior normal colonoscopyAmong 739 patients with a previous normal colonoscopy who had a positive mt-sDNA test, the prevalence of advanced colorectal neoplasia remained 19.1%, suggesting that prior screening does not eliminate the need for follow-up colonoscopy after a positive stool test. (Clin Transl Gastroenterol)
-
LIVING WITH CRC
5-FU and capecitabine show distinct side-effect profiles in observational studyIn 91 patients receiving active chemotherapy, loss of appetite and nausea were more frequent with 5-FU, while diarrhea was less common with capecitabine; the observational design does not permit causal conclusions. (Diagnostics)
-
RESEARCH
Early-onset rectal cancer with pMMR/MSS phenotype reported in patient with germline PMS2 variantA 41-year-old woman with low rectal adenocarcinoma showed retained MMR protein expression and microsatellite stability, yet germline testing confirmed a pathogenic PMS2 frameshift variant, illustrating that pMMR/MSS findings do not exclude hereditary risk in early-onset disease. (Front Med)
This week's research spans liquid biopsy validation, screening follow-up, symptom profiling, and the complexities of hereditary risk assessment in early-onset disease.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. Readers are added at their own request, by sign-up or through Evolution Labs.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data